Background Cell-free fetal DNA (cffDNA) non-invasive prenatal testing (NIPT) is rapidly expanding, and is being introduced at varying rates depending on country and condition.
Introduction
Non-invasive prenatal testing (NIPT) uses cell-free fetal DNA (cffDNA) that is present in maternal plasma, and is believed to originate from the trophoblast. It was first detected by Lo et al. in 1997 , and was used to indicate the presence of the Y chromosome in order to diagnose fetal sex. 1 NIPT can now be used to test for aneuploidy, and single-gene disorders such as cystic fibrosis, Huntington's disease, or thanatophoric dysplasia. [2] [3] [4] [5] [6] It has the advantage of being non-invasive, avoiding the 0.5-1.0% risk of miscarriage associated with amniocentesis/chorionic villus sampling, 7 and allows for timely therapeutic intervention in conditions such as congenital adrenal hyperplasia (CAH). 8 cffDNA is cleared from plasma (in a matter of hours) following delivery, thereby ensuring individuality for each pregnancy. 9 Non-invasive prenatal testing also has health economic implications, eliminating the need to give all women testing rhesus D-negative anti-D immunoglobulin prophylaxis.
NIPT is being introduced into routine antenatal care across the world at differing rates, largely influenced by technological advances facilitated by the commercial sector. Current guidance in North America and from the International Society for Prenatal Diagnosis advises a positive NIPT for aneuploidy to be confirmed by invasive testing, [10] [11] [12] because of the low risk of a false-positive result secondary to confined placental mosaicism (CPM). Inconclusive results occur in up to 8.1%, 10 with a repeat sample being successful in up to 80% of participants. 13 Several systematic reviews and meta-analyses evaluating test accuracy have been published. [14] [15] [16] [17] [18] These have several limitations, however: (i) they evaluate individual conditions (e.g. fetal sex, rhesus D status, or aneuploidy), thus not allowing comparison; (ii) they have a high risk of bias, as they include case-control studies; (iii) they use inferior statistical techniques for meta-analysis; and (iv) they include studies with a significant risk of verification bias, as not all participants undertake a reference test (e.g. karyotype). The aim of our article was to produce the most comprehensive systematic review and meta-analysis of NIPT, and in order to reduce bias we only included cohort studies, 19 we performed bivariate meta-analysis where possible, and included all indications for antenatal use, so as to enable a more uniform comparison for the use of NIPT in clinical practice. We also aimed to assess aspects of test accuracy that might influence how cffDNA is implemented in the clinical pathway: e.g. the effect of technique on accuracy and evaluation of false-positive, false-negative, and inconclusive results.
Methods
This review was performed according to recommended methods, and used a protocol that was designed and registered a priori (PROSPERO CRD42014007174).
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Identification of studies
The Medline, Web of Science, Embase, CINAHL, and Cochrane Library databases were searched for relevant articles by FLM. Grey literature and reference lists were hand-searched. The search terms used were 'noninvasive', 'non-invasive', 'non invasive', 'prenatal diagnosis', 'cell free fetal DNA', and 'cell-free fetal DNA'. The full search strategy is available in Appendix S1. The date of publication was limited from 1997 to 13 April 2015. There was no limitation on language.
Study selection
Study selection was performed in duplicate (FLM and RKM), involving screening of titles and abstracts, then reviewing the full manuscripts of selected articles. Disagreements in selection were resolved by MDK. Articles were included based on the following criteria.
Population
Women with a singleton pregnancy, any gestation. Populations could include women of varying risk, with women defined as being at high risk attending for testing because of pre-existing risk factors: a personal or family history of the condition being tested for; deemed high-risk on routine biochemical screening; abnormal ultrasound scan; and/or older maternal age. Women were considered to be at low risk if they had none of the above risk factors.
Test
Non-invasive prenatal testing (NIPT) based on cffDNA in maternal blood, irrespective of condition being examined.
Reference standard
Studies must have compared all of the cffDNA results with either karyotype results or birth outcome (either blood sample or phenotype), as appropriate, in all participants.
Study design
Cohort studies.
Exclusion criteria
Pre-implantation testing, fetal cell testing, case-control studies, case series with fewer than five participants.
Data extraction
Data were extracted in duplicate on the relevant 2 9 2 tables comparing the non-invasive test with the reference test used for definitive diagnosis. Data were also extracted on factors that may affect test accuracy: participant characteristics (e.g. obstetric history) and test characteristics [e.g. cut-offs used and test technique [e.g. polymerase chain reaction (PCR), massive parallel sequencing (MPS), mass spectrometry]. Information regarding false results and inconclusive results was obtained.
When a study used similar laboratory protocols on the same blood samples (e.g. different number of replicates performed), only the best results were included. When a study used different laboratory protocols on different blood samples, but the same type of test technique, these samples were grouped together for analysis. If a study subdivided samples based on population characteristics (e.g. high risk versus low risk for a condition, or first trimester versus second trimester versus third trimester), these were grouped together for the summary statistics and analysed as a subgroup, where appropriate.
Quality assessment
The quality of the studies was assessed using the QUADAS-2 tool. 24 
Data synthesis
For each study the 2 9 2 data were used to calculate sensitivity and specificity with 95% confidence intervals. Heterogeneity was explored by assessing the distribution of results in the Forest plots and Hierarchical summary receiver operating characteristic curves (HSROCs). Summary measures, including sensitivities, specificities, diagnostic odds ratios, and positive and negative likelihood ratios, along with 95% confidence intervals, were calculated using a bivariate logistic regression model with an unstructured correlation. This model allows for the correlation between sensitivity and specificity from the same study, and for the sensitivities and specificities to have different random effects. 25 Meta-analysis was performed when there were more than five studies per condition using STATA 13 (StataCorp. 2012, College Station, Texas; for more detail, see Appendix S2). Subgroup analysis and meta-regression was planned a priori to assess effects of study-level covariates on test accuracy, namely: population characteristics (level of risk for condition where appropriate, i.e. not performed in fetal sex or rhesus D); test technique (e.g. PCR or MPS) and quality aspects according to QUADAS-2. We used subgroup analyses (as opposed to meta-regression) to assess the influence of all categorical covariates due to model convergence difficulties. 26 
Results
The search revealed 4433 studies for inclusion. After reviewing the full article, 117 studies 1,27-143 were eligible, reporting on 18 different conditions and 472 935 tests (Figure S1 ). The study characteristics are outlined in Table S1 .
We were able to produce summary results using the fully unstructured bivariate model for fetal sex, rhesus D, trisomy 21, trisomy 18, and monosomy X (Table S2) . For trisomy 13, despite a sufficient number of studies (n = 15), there was no heterogeneity in specificities across studies so the bivariate model, which takes into account the correlation between the sensitivities and specificities, failed to converge, and consequently we fitted a univariate model. Because of this, these results are less methodologically robust. The HSROCs are presented in Figure S2 , and the results from our subgroup analyses are presented in Table S2 .
In five studies (n = 394 130 tests) there was differential verification of results, in that some participants had their result confirmed by karyotype and others by phenotype. 35, 91, 93, 114, 133 These five studies all assessed fetal aneuploidy and used NIPT as a screening test in a low-risk population. A sensitivity analysis removing these five studies demonstrated no significant effect on the summary results, thus these studies are included in all analyses and Forest plots.
The following 12 conditions had insufficient studies for meta-analysis: rhesus C, rhesus E, 47XXX, 47XXY, 47XYY, trisomy 16, congenital adrenal hyperplasia, deletion-duplication syndromes, sickle cell anaemia, thalassaemia, human platelet antigen 1a, and KEL 1. The Forest plots of these 12 conditions are presented in Figure S3 .
Methodological quality of included studies
This was assessed according to the Quality Assessment tool for Diagnostic Accuracy Studies (QUADAS-2), 24 and the results are presented in Figure S4 and further described in Appendix S3.
False results and inconclusive results
Reporting of causes and implications of false-positive, falsenegative, and inconclusive results was poor, and varied across all conditions (Table S3 ). The included studies reported an inconclusive result rate of 0.32-5.30%. This issue was further compounded by a myriad of varying quality control (QC) standards, with some studies excluding samples that failed their QC, and others implementing no QC steps and therefore reporting some results as false negatives that other studies would have excluded from the analysis. Some studies investigated the reasons for their false and inconclusive results and reported these clearly, accounting for all samples. Other studies reported inconclusive results as false negatives or did not report them at all. We describe these results in more detail for each of the conditions investigated. Table S2 .
Results from bivariate meta-analysis
No significant effect on sensitivity was found with test technique; however, there was a difference in specificity DNA degradation/pipetting error/incorrect neonatal blood testing.
Trisomy 21
Thirty-one studies (148 344 tests) assessed trisomy 21 and are represented in Figure 3a . Bivariate meta-analysis produced a summary sensitivity of 0.994 (95% CI 0.983-0.998) and specificity of 0.999 (95% CI 0.999-1.000), and a positive likelihood ratio of 1720 (95% CI 1111-2662) and a negative likelihood ratio of 0.006 (95% CI 0.002-0.017). Test technique and population risk had no significant effect. For trisomy 21, 14/31 studies reported inconclusive results. Of these, seven studies documented an explanation (in order of frequency): assay failure; confirmed low fetal fraction; no reason given; presumed low fetal fraction/inadequate sequencing depth. The most common reasons given for false results were: confirmed low fetal fraction; confirmed mosaicism; no reason given; test failure; maternal copy number variant (CNV).
Trisomy 18
Twenty-four studies (146 940 tests) assessed trisomy 18 and are represented in Figure 3b . Bivariate meta-analysis produced a summary sensitivity of 0.977 (95% CI 0.952-0.989) and specificity of 0.999 (95% CI 0.998-1.00), and a positive likelihood ratio of 1569 (95% CI 810-3149) and negative likelihood ratio of 0.023 (95% CI 0.011-0.048). Neither test technique nor population risk had a significant effect. For trisomy 18, 12/ 24 studies reported inconclusive results. Of these, seven studies documented an explanation (in order of frequency): low fetal fraction; test failure; no reason given; mosaicism. The most common reasons given for false results were: confirmed low fetal fraction; confirmed mosaicism; presumed low fetal fraction/human error; maternal CNV; no reason given.
Monosomy X
Eight studies (6712 tests) assessed monosomy X and are represented in Figure 3c . Bivariate meta-analysis produced a summary sensitivity of 0.929 (95% CI 0.741-0.984) and specificity of 0.999 (95% CI 0.995-0.999), and a positive likelihood ratio of 1337 (95% CI 213-8407) and negative likelihood ratio of 0.071 (95% CI 0.017-0.292). There was no significant difference with test technique. It was not possible to assess the effect of population risk, as there were insufficient low-risk studies. For monosomy X, five of eight studies reported inconclusive results. Of these, three studies documented an explanation (in order of frequency): low fetal fraction; presumed human error; and no reason given. The most common reasons given for false results were: mosaicism and no reason given.
The five aneuploidy studies that evaluated an unselected obstetric population reported inconclusive results, with rates of 0.29-5.10%, and provided the same reasons for their false and inconclusive results as with the high-risk aneuploidy populations.
Trisomy 13: univariate meta-analysis Sixteen studies, which equates to 134 691 tests, examined trisomy 13 (Figure 3d ). There was a summary sensitivity of 0.906 (95% CI 0.823-0.958) and specificity of 1.00 (95% CI 0.999-1.00). The positive likelihood ratio was 453 (95% CI 26-7864) and negative likelihood ratio was 0.188 (95% CI 0.080-0.44039), with a diagnostic odds ratio of 2788 (95% CI 285-27252). For trisomy 13, six of 16 studies reported inconclusive results. Of these, four studies documented an explanation for inconclusive results: low fetal fraction; different fragmentation rate; contamination; assay failure; and human error. The only reason given for false results was confirmed low fetal fraction.
Results where meta-analysis not possible
The results for these conditions are presented as Forest plots in Figure S3 .
Clinical application for NIPT for trisomy 21 screening
Using published data from the National Down Syndrome Cytogenetic Register (NDSCR) 2012 annual report, we have calculated the estimated outcomes (livebirth rate, invasive test rate, euploid pregnancy loss rate, and undiagnosed aneuploidy livebirth rate) from the current standard combined first-trimester trisomy 21 screening and from a pathway with NIPT as both contingent (i.e. NIPT offered to women with a positive screening after first-trimester combined screening) and first-line screening for a population of 100 000 women using crude rates (Table S4) . 144 We use the prevalence reported by NDSCR (trisomy 21, 2.2 per 1000 women; trisomy 18, 0.64 per 1000; trisomy 13, 0.26 per 1000). 1 This assumes that standards for the first-trimester combined screening are 'achievable', as described by Fetal Anomaly Screening Programme (FASP) guidance (i.e. for trisomy 21 a detection rate of 85% for a screen-positive rate of 2%. 145 For NIPT the summary measures are those from our meta-analysis. For the contingent screening model the cut-off for high risk is 1 : 1000 from first-trimester combined screening, with a detection rate of 96% and false-positive rate of 12%. 146 This model assumes that all women accept screening when offered, as it is not yet possible to determine what the uptake of NIPT would be if offered as a first-line test. It also assumes that all women are required to have an invasive test for karyotyping after a screen-positive result from combined or NIPT prior to considering termination of pregnancy, thus the invasive test rates will be higher than in a real-life population. It assumes a 0.5% pregnancy loss rate from invasive testing. 146 These data demonstrate the influence of disease prevalence on test performance. If we compare combined screening with a 1 : 150 cut-off (i.e. current UK National Health Service practice) with NIPT as a first-line test, we can reduce the invasive test rate from 2000 to 319 per 100 000 women, the euploid pregnancy loss rate from 9 to 1 per 100 000, and the undiagnosed trisomy 21 live birth rate from 32 to 1 per 100 000. If NIPT was used as a contingent screening test for a 1 : 1000 combined screening cutoff (i.e. as a second test following a positive combined screening result at a 1 : 1000 cut-off), then these figures are reduced even further compared with combined screening using a 1 : 150 cut-off: from 2000 to 222 per 100 000 women invasive test rate; from nine to zero euploid pregnancy loss rate, although there is less of a reduction in the undiagnosed trisomy 21 live birth rate, from 32 to 10 per 100 000. If NIPT was used as a contingent screening test for a 1 : 150 combined screening cut-off, then these figures are: 2000 per 100 000 women invasive test rate; 0 euploid pregnancy loss; and an undiagnosed trisomy 21 live birth rate of 34 per 100 000. A two-stage contingent screening pathway with a 1 : 1000 cut-off when compared with NIPT as a first-line test affords a reduction in false-positive results (12 versus 100 per 100 000 women) that are found at the time of NIPT, as the prevalence of disease in the population now undergoing NIPT is much higher. This is at the expense of a ten-fold increase in undiagnosed aneuploidy live births (one versus ten per 100 000 women) because of the increased number of false negatives at the first stage of screening that do not undergo NIPT. A cutoff of 1 : 150 at the first stage for the combined test compared with a 1 : 150 cut-off for NIPT as a contingent screening test has little effect on the number of false negatives (33 versus 34) ; however, the invasive test rate is reduced (2000 versus 188 per 100 000 women).
Discussion
Main findings
Our results demonstrate that for fetal sex and rhesus D status, cffDNA-based NIPT has a high sensitivity and specificity. For the aneuploidies trisomy 21, and in particular trisomy 18 and trisomy 13, we have demonstrated improved accuracy from other recent systematic reviews, likely to be linked with technological developments.
Importantly we found that false results and inconclusive results were poorly reported across all conditions.
Strengths and limitations
This review was performed according to a rigorous methodology, with efforts made to reduce bias in participant selection and clinical applicability by excluding casecontrol studies, performing bivariate meta-analysis and meta-regression analysis, and assessing the impact of differential verification (i.e. different reference standards). Bivariate meta-analysis is the recommended approach for the meta-analysis of diagnostic test accuracy studies. This is because a conventional univariate analysis makes assumptions that are known not to be tenable (that the sensitivity and specificity from the same study are independent); however, the bivariate meta-analysis model is a technically difficult model to fit, and it is well known that these models might not converge when there are a small number of studies, or when there are zero cells (i.e. sensitivity or specificity close to 100). 26 We observed no indication that other model fits were unstable, and so have no reason to be concerned about the statistical validity of the other results. Our review also evaluates more conditions than previously. In addition, our article has been able to assess the impact of test technique and population risk. We were unable to evaluate the number of samples that failed QC measures, as this was reported in varying degrees. When considering the implementation of a new test, information regarding failed tests and inconclusive results is vital. 147, 148 We investigated the reasons for false-positive and falsenegative results within and across studies, and attempted to summarise these. This was again hampered by poor reporting, with a common reason cited of low fetal fraction, which is difficult to measure accurately and thus has led to variations in approach between studies. It is especially important to consider this further, as low fetal fraction has been shown to be associated with trisomy 18 and triploidies.
A limitation of this work is that it was not possible to account for the many subtle differences in laboratory techniques, such as comparing the different combinations of genetic markers used for each condition, or the myriad of adjustments made to bioinformatics algorithms, as these were so varied. This is where the results from the large studies in screening populations are especially important, as there is QC across laboratories and standardisation of techniques. 35, 91, 93, 114, 133 In the process of publishing this review the search was re-run from April 2015 to September 2015, in view of the rapid progression in this area. This yielded 78 new citations, of which 11 additional papers would be eligible for inclusion, with 10 191 women in total. 3, [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] These studies examine fetal sex (n = 436 women), rhesus D status (n = 2965), trisomy 21 (n = 6661), trisomy 18 (n = 6701), trisomy 13 (n = 6495), and monosomy X (n = 40), which equate to a small proportion of additional tests, compared with the studies that we have already analysed. There is also now one study that investigates thanatophoric dysplasia (n = 108), although this cannot be included in a meta-analysis as it is the only study to look at this condition thus far. As the search was under a year old when the publication was accepted, we have not included these 11 studies in our results. We are confident that if these studies were included they would not impact on our results and conclusions.
Interpretation
It is recognised that there are fewer studies in our metaanalyses for trisomy 13 and monosomy X, compared with a previous large meta-analysis, 14 this is the result of excluding case-control studies and limiting studies to singleton births. This has led to us reporting higher summary sensitivities and specificities than existing analyses, demonstrating how NIPT is advancing, and supporting the belief that NIPT will be used as the first-line screening test in the future. Our clinical application model has highlighted the importance of the low prevalence of disease on the positive predictive value and false-positive rate in the case of aneuploidies. Although positive and negative predictive values are useful indicators of test accuracy, as they take into account disease prevalence, 159 we have not presented these values within this article because of variation in disease prevalence among the study populations included.
Conclusion
This work demonstrates that there is a sufficient body of evidence for the accuracy and reproducibility of cffDNA-based NIPT to allow its introduction into routine clinical practice within the UK; however, its role is yet to be decided.
Implications for clinical practice
The findings of this analysis support the use of NIPT as a diagnostic test for fetal sex and rhesus status because of the nature of these conditions and the populations being tested. For assessment of aneuploidy the test must be considered a 'screening test', despite high accuracy, because of the low prevalence of disease and influence of biological factors such as CPM. We are aware that the National Screening Committee (NSC) is currently reviewing all evidence for aneuploidy, and is likely to recommend NIPT as a contingency screening test in the UK (Dr Pranav Pandya, pers. commun., 2015). For trisomy 21 screening this will ensure access to an accurate, non-invasive test, and will ensure equity for many more women (i.e. the test threshold has less of an impact on offering invasive testing, and the test can be offered throughout gestation not just in a small first-trimester window), although this must be balanced with consideration of the important ethical repercussions that need to be addressed (i.e. a test that can assess for multiple conditions and those with a milder phenotype, and also test for conditions within the mother, e.g. sexchromosome anomaly or cancers). 160 There are also counselling implications as access to a non-invasive, highly accurate test still needs careful consideration by parents.
Implications for future research
The authors recommend that the same rigorous assessment of evidence and accuracy performed here be applied to studies with multiple pregnancies once the evidence base is sufficient.
The National Institute for Health Research (NIHR)-funded RAPID study that has used NIPT in an NHS setting for women in whom combined testing gave a risk of ≥1 : 1000 will soon be published. This study aims to: assess the uptake of NIPT, and whether if the addition of NIPT to the trisomy 21 pathway affects the uptake of trisomy 21 screening and invasive testing; provide a detailed health economic evaluation using a tool developed in conjunction with the UK NSC; find optimal ways to deliver education to women and healthcare professionals; and calculate the sensitivity and specificity of NIPT for aneuploidy when performed in an NHS regional genetics laboratory. The results from our review indicate the latter (accuracy results from an NHS regional genetics laboratory) will be an important outcome, as it will remove the influence of results from the commercial sector and poor reporting. This will allow for improved QC, enable the continued assessment on a national basis, and ensure that the cost of NIPT will improve further. Similarly, the conditions for which NIPT will be used are likely to increase: 11 studies that examined single-gene mutations and microdeletions could not be included in our meta-analysis because they included fewer than five participants. Even whilst writing this review larger studies are being reported on these conditions. 161 Any economic evaluation of this first-line screening with NIPT would also need to include maintaining access to a high-quality first-trimester ultrasound scan, including nuchal translucency (NT) assessment, to allow dating, viability, multiple pregnancy, structural anomaly, and adnexal assessment, and importantly the assessment of the risk of cardiac anomalies and increased pregnancy loss associated with raised NT.
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